Keywords

1. Apatinib colorectal cancer treatment
2. Advanced colorectal cancer therapy
3. Apatinib safety profile
4. Apatinib adverse effects
5. Colorectal cancer survival analysis

Colorectal cancer (CRC) stands as a prevalent and lethal disease, driving oncologists to relentlessly search for more effective treatments for advanced stages. Apatinib, a tyrosine kinase inhibitor, has emerged as a potential line of treatment after conventional therapies have failed. A study conducted by Li Ning Ning and colleagues from the PUMC Hospital in Beijing has evaluated Apatinib’s effects on patients with advanced colorectal cancer, offering valuable data on its efficacy and safety.

Published in the ‘Zhongguo Yi Xue Ke Xue Yuan Xue Bao’ on 2019 April 28, with the DOI 10.3881/j.issn.1000-503X.10376, the research analyzed retrospective data from 16 patients with advanced CRC who underwent treatment with Apatinib after previous therapies did not yield the desired results. The main objective was to assess the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety profile, and prognostic factors.

The study’s findings revealed an ORR of 7.1% and a DCR of 50%, with the median PFS and median OS recorded at 3 and 6.5 months, respectively. When examining safety, the most common grade 3 adverse events were hypertension (37.5%) and proteinuria (25%). No grade 4 adverse event was reported during the study, signifying that Apatinib, while showing moderate clinical activity, had a safety profile that could be managed in a clinical setting.

These results are pivotal for the medical community as they provide an understanding of Apatinib’s role in the treatment landscape of advanced CRC. The modest efficacy demonstrates that while Apatinib is not a cure-all, it holds the potential to offer benefit to those who have exhausted other options. Moreover, the absence of severe (grade 4) toxicities suggests that Apatinib might be a suitable option for patients with advanced disease, keeping in mind the proper management of adverse events.

Experts in oncology have weighed in on the findings with cautious optimism. The manageable safety profile of Apatinib coupled with its modest efficacy could be a stepping-stone to more refined treatments or administrated in combination with other therapies. There is a consensus that more extensive and controlled studies are necessary to fully understand Apatinib’s place in CRC treatment.

For patients battling advanced CRC, the news of any progress is welcome. The study presents a glimmer of hope with Apatinib potentially adding months to survival times. However, the associated risks, such as hypertension and proteinuria, raise valid concerns for patients considering this therapy as part of their treatment regimen.

The study conducted by Li Ning Ning and colleagues is a valuable addition to colorectal cancer research, providing insights into Apatinib’s utility. It opens pathways for further investigation into optimizing the dosage and timing of Apatinib administration, possibly in conjunction with other treatments, to improve outcomes for patients with CRC.

References

1. Li, N.N., Zhou, J.F., Zhao, L., Ying, H.Y., & Jia, N. (2019). Efficacy and Safety of Apatinib in Treating Advanced Colorectal Cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. doi:10.3881/j.issn.1000-503X.10376.

2. National Cancer Institute. (2022). Colorectal Cancer—Patient Version. Retrieved from [Link to the National Cancer Institute’s page on CRC].

3. American Cancer Society. (2022). Colorectal Cancer Facts & Figures 2020-2022. Retrieved from [Link to American Cancer Society’s recent fact sheet on CRC].

4. FDA. (2022). FDA-Approved Drugs: Apatinib. Retrieved from [Link to FDA page on Apatinib approved usages].

5. ClinicalTrials.gov. (2022). A List of Clinical Trials Involving Apatinib. Retrieved from [Link to ongoing clinical trials involving Apatinib].